



7 CME

World Tuberculosis Day

“It’s Time!”

One Day Seminar

April 27, 2019 | 09:00 – 18:30

Organized By:



Venue:

Fairmont
BAB AL BAHR
ABU DHABI

CHAIRMAN



Dr. Jehad Abdalla, M.D.

ID Consultant, Head of IPCC,
Al Rahba Hospital, Abu Dhabi, UAE

Jehad Abdalla, M.D. is an American board-certified in both Internal Medicine and Infectious Diseases, currently works as an Infectious Diseases consultant at Al Rahba hospital in Abu Dhabi, head of the infection control and prevention committee and chairperson of antibiotic stewardship program and at Al Rahba hospital. He is a member of HAAD TB strategic planning and development team, also member of the Infection control scientific committee in SEHA, he is an invited speaker in many Infectious Diseases and Infection control conferences including SEHA International Conference on Prevention and Control of Infection. Dr. Abdalla has a special interest in Tuberculosis as well as HIV management.

SPEAKERS



Dr. Suaad Aljaberi

Molecular epidemiologist
Infection diseases specialist
International professional trainer



Dr. Stefan Weber

Consultant Physician
Sheikh Khalifa Medical City



Dr. Ahmed Abbass

Lecturer Chest Medicine
Pulmonologist at SEHA -AHS-
Occupational Health Clinic. Infectious
Disease Control Department



Mr. Elias Tannous

Infection control specialist
Cleveland Clinic Abu Dhabi



Dr. Ahmed Khudhair Abbas

Public Health specialist,
Senior officer TB
Communicable Diseases Department

OVERVIEW

The history of anti-tuberculosis drug resistance is recent, emerging just over 60 years ago with the development of anti-tuberculosis drugs. For decades the problem was identified in localized areas, among patients treated at reference centers in industrialized countries. With the discovery of rifampicin (RMP) in 1966,6 and the expansion of its use between 1970 and 1990, patients who were already carriers of isoniazid (INH) resistant Mycobacterium tuberculosis strains became resistant to RMP. This was the start of a progressively growing problem, multidrug resistant tuberculosis (MDR-TB, defined as resistance to at least both INH and RMP7), which has reached epidemic proportions in some countries. It is crucially important to recognize the individual and collective factors responsible for the heterogeneous global distribution of drug resistance, and to identify those populations at highest risk, in order to be able to develop the most appropriate case finding strategies. (Caminero, 2010)

OBJECTIVES

- Describe the national and global epidemiology of MDR and XDRTB
- Discuss new update from WHO regarding treatment guidelines for MDR TB
- Explain who is at higher risk for MDRTB
- Discuss interpretation of molecular tests for drug resistance.
- Explain the general principles of MDR/XDRTB treatment.
- Discuss the challenges in managing MDR/XDRTB

SEMINAR WILL COVER

- Resistance Trends for MDR –TB , Abu Dhabi, 2010-2015
- New update in Medicines recommended for the treatment of RR-TB and MDR-TB
- Updated activities for monitoring treatment response

WHO SHOULD ATTEND

Respiratory Therapy specialists, Clinical Support, & Clinical Toxicology, CSSD specialists, Medical Imaging/ Medical Laboratory, Medical Practitioner, Family & General Medicine Intensive, Critical Care, & Internal Medicine, Pathology, Pharmacy, Radiology, Surgery/Surgeons, Nurse

AGENDA

Saturday- April 27, 2019

Reception coffee, Pre-test : 08:00 – 09:00

09:00	10:00	Epidemiology and Genetic Diversity of Mycobacterium Tuberculosis.	Dr. Suaad Al Jaberi
10:00	10:05	Discussion Period	
10:05	11:05	Multi Drug-Resistant Tuberculosis, The Whole Story.	Dr. Jehad Abdalla
11:05	11:10	Discussion Period	
11:10	11:40	Coffee Break	
11:40	12:40	Interferon Gamma Release Assay (IGRA) – And Latent Tuberculosis	Dr. Stefan Weber
12:40	12:45	Discussion Period	
12:45	13:45	Preventing the Transmission of M. Tuberculosis in Health-Care Settings	Dr. Elias Tannous
13:45	13:50	Discussion Period	
13:50	14:50	Latent Tuberculosis Infection (LTBI)	Dr. Ahmed Abbas
14:50	14:55	Discussion Period	
14:55	15:55	Prayer and Lunch Break	
15:55	16:55	Side Effects of Anti-Mycobacterial Agents, All What You Need To Know.	Dr. Jehad Abdalla
16:55	17:00	Discussion Period	
17:00	18:00	DOT Program For TB Control in Abu Dhabi.	Dr. Ahmed Khudhair
18:00	18:05	Discussion Period	
18:05	18:30	Conclusion & Post-Test	



OUR PRIORITY

NAT PRIORITY IS TO OFFER THE HIGHEST QUALITY HEALTHCARE TRAINING COURSES, WORKSHOPS, AND SEMINARS AND TO BECOME THE FIRST CHOICE FOR HEALTHCARE STAFF DEVELOPMENT AND CONTINUOUS MEDICAL EDUCATION IN THE ARAB REGION.

| FEES

190 AED

| VENUE

FAIRMONT BAB AL BAHR HOTEL
ABU DHABI



+971 02 4957060
+971 50 3935151



@n_altamayuz



nahdat altamayuz



nahdataaltamayuz



nahdat_altamayuz

www.nahdataaltamayuz.com